1132 Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients

Andreas Saltos, Hong Zheng, Christy Arrowood, Georgia M. Beasley, James Ronald, Ghassan El‐Haddad, Uzma Khan, Luiziane Guerra-Guevara, Steven L. Wolf, Lin Gu, Xiaofei Wang, Mark G. Cantwell, Scott Antonia, Amer A. Beg, Neal ReadyRegular 2022 · DOI

Introduction

Immune checkpoint inhibitors (ICIs) have transformed the oncology landscape, yet a significant portion of patients fail to respond because their tumors are immunologically "cold." These tumors lack the necessary T cell infiltration and activation required for a successful immune response. One primary obstacle is the dysfunction or absence of activated conventional dendritic cells (cDCs) within the tumor microenvironment (TME). cDCs are essential for "presenting" tumor antigens to the immune system and priming T cells.

To address this, researchers have developed MEM-288, a conditionally-replicative oncolytic adenovirus. MEM-288 is designed to selectively infect cancer cells and deliver a dual genetic payload: human interferon beta (IFNβ) and a membrane-stable form of CD40-ligand (MEM40). This study evaluates how this dual-track activation of the innate and adaptive immune systems can turn a localized injection into a systemic antitumor response.

The MEM-288 Mechanism: Synergizing Innate and Adaptive Signals

MEM-288 functions as an <i>in situ</i> vaccine factory. By encoding both IFNβ and MEM40, the virus targets two critical pathways for cDC activation:

  1. IFNβ (Type 1 Interferon): Triggers innate antiviral defenses and promotes an environment conducive to immune cell recruitment.
  2. MEM40: Acts as a potent "on switch" for dendritic cells by binding to CD40, facilitating their maturation and ability to prime T cells.

Preclinical studies in mouse melanoma and lung tumor models demonstrated that the co-expression of these two molecules is significantly more effective than either alone. This synergy induces a dramatic increase in cDC migration to the lymph nodes, which are the primary sites for T cell training and activation.

Preclinical Insights: Generating "Stem-Like" Immunity

Using flow cytometry and single-cell RNA sequencing (scRNA-seq), the researchers mapped the cellular changes following MEM-288 administration. A key finding was the generation of TCF1+ stem-like CD8+ T cells. These specific T cells are highly valued in immunotherapy because they act as a self-renewing reservoir, providing a continuous supply of effector T cells to combat the tumor over time. Their presence is strongly associated with positive responses to ICIs.

Furthermore, the therapy demonstrated a robust abscopal effect. In murine models, treating a single primary tumor led to the regression of distant, untreated tumors and lung metastases. This suggests that the local viral injection successfully programmed the immune system to recognize and attack cancer cells throughout the body, regardless of their location.

Clinical Translation: Phase 1 Results in NSCLC

The promising preclinical data is currently being validated in an ongoing Phase 1 dose-escalation trial (NCT05076760). The study involves patients with various solid tumors, with early focus on non-small cell lung cancer (NSCLC).

Initial data from the first two NSCLC patients treated with a single low-dose intralesional injection (1e10 viral particles) of MEM-288 are encouraging:

  • Tumor Shrinkage: The injected tumors shrank by 31% and 53%, respectively.
  • TME Remodeling: Post-treatment biopsies confirmed a substantial increase in overall CD8+ T cell infiltration.
  • Immune Priming: Consistent with the mouse models, there was a notable increase in TCF1+ stem-like CD8+ T cells within the human tumor tissue.

Discussion and Future Outlook

The ability of MEM-288 to remodel the TME and induce systemic immunity marks a significant step forward for oncolytic viral therapy. By focusing on the activation of cDCs, the therapy provides the "danger signals" necessary to convert cold tumors into hot ones.

While the clinical results are early, the correlation between the preclinical "stem-like" T cell recruitment and the observed tumor shrinkage in humans is a strong proof-of-concept. The next phases of research will focus on:

  1. Determining the optimal dose in the ongoing escalation study.
  2. Evaluating the systemic effects on T cells circulating in the peripheral blood.
  3. Launching an expansion arm to combine MEM-288 with anti-PD1 antibodies, specifically targeting NSCLC patients who have previously failed standard immunotherapy.

By combining direct viral oncolysis with potent immune-activating transgenes, MEM-288 may provide a vital tool for overcoming resistance to current checkpoint inhibitors.

Summary updated

Abstract

<h3>Background</h3> Oncolytic viral therapies are thought to act through both direct killing of tumor cells and activation of conventional dendritic cells (cDCs), resulting in an enhanced T cell response. However, cDC activation has not been optimized with current therapies. MEM-288 is a conditionally-replicative oncolytic adenovirus encoding transgenes for human interferon beta (IFNβ) and a recombinant membrane-stable form of CD40-ligand (MEM40), two potent activators of the immune response and cDCs. <h3>Methods</h3> We evaluated intralesional adenoviral delivery of MEM40 and IFNβ to activate cDCs in mouse melanoma and lung tumor models. Flow cytometry and scRNA-seq were used to determine treatment impact on cDCs and T cells. Clinical translational research also investigated the immune response of intralesional administration of MEM-288 in patients with select solid tumors in an ongoing Phase 1 dose-escalation, multi-center, open-label trial (NCT05076760). Patient pre- and on-treatment tumor biopsies and peripheral blood were collected before and after MEM-288 treatment for immunologic evaluation. <h3>Results</h3> In preclinical studies, MEM40 and IFNβ in situ co-expression induced higher cDC activation than either molecule alone, in addition to a dramatic increase in lymph node migration, a systemic anti-tumor CD8<sup>+</sup> T cell response, and regression of established tumors in a manner dependent upon type 1 cDCs. MEM40 and IFNβ expression enhanced generation of both Granzyme B<sup>+</sup> CD8<sup>+</sup> T cell effectors as well as TCF1<sup>+</sup> stem-like CD8<sup>+</sup> T cells that are known to be strongly associated with response to immune checkpoint inhibitors (ICIs). Intralesional therapy with MEM40 and IFNβ expressing adenovirus synergized with ICIs, leading to effective control of distant tumors and lung metastases. Notably, these preclinical results are translating into the clinical setting. Pre- and on-treatment biopsies from the initial 2 non-small cell lung cancer (NSCLC) patients on study were evaluated for TME impact of MEM-288 treatment. A single intralesional injection of low dose cohort MEM-288 (1e10 viral particles) resulted in shrinkage of the injected tumor (-31 and -53%), concomitant with substantial increases in overall CD8<sup>+</sup> T cells and TCF1<sup>+</sup> stem-like CD8<sup>+</sup> T cells. Studies to determine systemic effects on T cells are ongoing. <h3>Conclusions</h3> MEM40 and IFNβ expression induces strong remodeling of the TME in both murine models and solid tumor patients. Preliminary safety, antitumor, and immune response data in the ongoing MEM-288 clinical trial is also encouraging. Following completion of the monotherapy study, an expansion arm is planned where MEM-288 will be combined with anti-PD1 antibody in patients with advanced NSCLC refractory to ICI. <h3>Ethics Approval</h3> The studies described received IRB approval (Moffitt: Adverra IRB, # Pro00060205, Duke: DUHS IRB, #Pro00109517) prior to commencement, and in the clinical trial described all participants gave informed consent before taking part.
BibTeX
@inproceedings{saltos2022impact,
  author = {Andreas Saltos and Hong Zheng and Christy Arrowood and Georgia M. Beasley and James Ronald and Ghassan El‐Haddad and Uzma Khan and Luiziane Guerra-Guevara and Steven L. Wolf and Lin Gu and Xiaofei Wang and Mark G. Cantwell and Scott Antonia and Amer A. Beg and Neal Ready},
  title = {{1132 Impact of intralesional oncolytic viral therapy targeting <i>in situ</i> activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients}},
  booktitle = {Regular},
  year = {2022},
  doi = {10.1136/jitc-2022-sitc2022.1132},
}
Figure